The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 29, 2020

Filed:

Oct. 10, 2018
Applicant:

Loxo Oncology, Inc., Stamford, CT (US);

Inventors:

Mark Reynolds, Stamford, CT (US);

Charles Todd Eary, Longmont, CO (US);

Assignee:

Loxo Oncology Inc., Stamford, CT (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/439 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 9/20 (2006.01); A61K 31/498 (2006.01); A61K 9/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/439 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/1611 (2013.01); A61K 9/1623 (2013.01); A61K 9/1641 (2013.01); A61K 9/1652 (2013.01); A61K 9/1682 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/4825 (2013.01); A61K 31/498 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 35/00 (2018.01);
Abstract

6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.


Find Patent Forward Citations

Loading…